Aptorum Therapeutics Group is currently seeking to develop various drug molecules (including projects seeking
to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment
and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology and other disease areas.


Acticule focuses on clinical therapeutic development in infectious diseases, with major product categories include antiviral and bacteria anti-virulence candidates and they can be potentially developed into oral and injectable dosage forms. Acticule is currently establishing a Drug Discovery Center (“DDC”), which is equipped with fully automated robotic platforms for conducting high throughput screening to create a sustainable pipeline of well selected and tested drug candidates for preclinical and clinical studies


Videns focuses on large-scale strategic clinical development in neurodegenerative disease and imaging diagnosis innovation. Its current key projects include: (i) MRI-based medical imaging technology for the early diagnosis of Alzheimer’s disease; (ii) mTOR-independent activator of TFEB for autophagy enhancement and treatment of neurodegenerative diseases; and (iii) non-invasive retinal imaging for the diagnosis of Alzheimer’s disease.


Claves focuses on the clinical development in therapeutic candidates related to the field of gastroenterology. The potential candidates under review and potentially developed focus on the modulation of gut microbiota derived metabolites, for preventing or treating diseases. Claves is also exploring a gut microbiota modulation platform that can generate novel custom candidates capable of fine-tuning levels of gut metabolites, potentially treating a wide range of medical conditions.


Scipio focuses on the development of drugs and diagnostic methods in the field of oncology. Its current key project involves the development of novel anti-cancer agents from the quinoline class and molecular oncology of esophageal carcinoma.


Nativus focuses on natural health or the development of therapeutic drugs and food supplements based on extracts from natural ingredients, such as green tea, garlic and Chinese yam. Currently, Nativus focuses on women’s health and vision care, as its lead candidate deliberate the treatment of endometriosis and the alleviation of painful symptoms due to dysmenorrheal.


Aptorum Pharmaceutical Development ("APD") operates an in-house pharmaceutical development center which is now in the process of further expansion. The primary mission of APD is to facilitate the preclinical studies of our existing projects with engaging external contract research organizations that accredited cGLP, cGMP and cGCP standard in order to attain the required studies for submission to the regulatory authorities as part of the clinical development plan.


Smart-ACT stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACT platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACT platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs.

Terms of Use

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.